Financing led by Sutter Hill Ventures; company names new Chief Business Officer, adds independent board member

由 Sutter Hill Ventures 领投；公司任命新的首席商务官，增加独立董事

,

，

and establishes Scientific Advisory Board

并设立科学顾问委员会

NEW YORK

纽约

,

，

April 27, 2026

2026年4月27日

/PRNewswire/ -- Fathom Therapeutics, formerly Atommap Corp., a company that uses quantum chemistry and AI to design novel drug molecules by predicting their behavior inside living cells, today announced an oversubscribed $47 million Series A financing. Sutter Hill Ventures led the round, with participation from Chemistry, Alexandria Venture Investments, and Empire State Development's NY Ventures, among others..

/PRNewswire/ -- Fathom Therapeutics，前身为Atommap Corp.，是一家利用量子化学和人工智能通过预测药物分子在活细胞内的行为来设计新型药物分子的公司，今天宣布完成了超额认购的4700万美元A轮融资。本轮融资由Sutter Hill Ventures领投，Chemistry、Alexandria Venture Investments以及Empire State Development's NY Ventures等机构参与了投资。

Continue Reading

继续阅读

Fathom's founders are Huafeng Xu, PhD, CEO; Yujie Wu, PhD, Chief Technology Officer; and Jesus Izaguirre, PhD, Chief Computational Scientist.

Fathom的创始人是胡华峰博士，首席执行官；吴宇杰博士，首席技术官；以及耶稣·伊萨吉雷博士，首席计算科学家。

Fathom logo

Fathom 标志

Microcosmos, the company's drug design engine, uses proprietary algorithms to simulate protein motion at atomic resolution, generating data on dynamic behavior that has been difficult to capture at scale. These algorithms accelerate modeling of protein dynamics by 10,000x without compromising accuracy.

微宇宙公司（Microcosmos）的药物设计引擎利用专有算法在原子分辨率下模拟蛋白质运动，生成大规模难以捕捉的动态行为数据。这些算法在不降低准确性的前提下，将蛋白质动力学建模的速度提高了10,000倍。

The simulations, based on physics, enable generative design of small molecules that reshape protein behavior for the desired therapeutic effect..

基于物理学的模拟使得能够生成设计出重塑蛋白质行为的小分子，从而达到预期的治疗效果。

'Current drug discovery efforts are limited by reliance on static structures of isolated proteins,' said Huafeng Xu, PhD, Co-Founder and CEO of Fathom Therapeutics. 'Microcosmos is a world model of drugs in living cells that surpasses these limitations by translating accurate quantum mechanical calculations to measurable cellular outcomes.'.

“当前的药物发现工作受限于对孤立蛋白质静态结构的依赖，”Fathom Therapeutics联合创始人兼首席执行官胡华峰博士说道，“Microcosmos是一个活细胞中药物的世界模型，它通过将精确的量子力学计算转化为可测量的细胞结果，超越了这些限制。”

Microcosmos has demonstrated significant early momentum in guiding the discovery and optimization of molecules for multiple classes of targets and small molecule modalities. In one case, the Fathom discovery team used Microcosmos to generate novel degraders against an 'undruggable' target. Within six weeks, the platform produced potent, highly selective candidates that are now being optimized for advancement into the clinic to address a major unmet medical need..

微宇宙在指导多类靶点和小分子模式的分子发现与优化方面展现了显著的早期势头。在一个案例中，Fathom 发现团队利用微宇宙生成了针对一个“不可成药”靶点的新型降解剂。在六周内，该平台生成了强效且高度选择性的候选分子，目前这些分子正在被优化以推进到临床阶段，从而满足一项重大的未竟医疗需求。

'We backed Huafeng because he wanted to rethink how machines understand molecules, combining the best of physics and machine learning to actually move the frontier in computational drug design,' said Keith Loebner, Managing Director at Sutter Hill Ventures.

“我们支持华峰，因为他想重新思考机器如何理解分子，结合物理和机器学习的最佳方法，真正推动计算药物设计的前沿，”Sutter Hill Ventures董事总经理Keith Loebner表示。

'He and the world-class team he's assembled have demonstrated that their approach not only works, but works better than we imagined. We're proud to lead this round, turning Fathom's field-defining molecular design capability into new medicines for patients.' Founded in 1962, Sutter Hill Ventures' previous investments include NVIDIA, Snowflake, Pure Storage, Corcept Therapeutics, GRAIL, and Forty Seven..

“他和他组建的世界级团队已经证明，他们的方法不仅有效，而且比我们想象的更好。我们很自豪能够主导这一轮投资，将Fathom定义领域的分子设计能力转化为患者的新型药物。” Sutter Hill Ventures成立于1962年，其之前的投资项目包括NVIDIA、Snowflake、Pure Storage、Corcept Therapeutics、GRAIL和Forty Seven。

The new funding will accelerate the scaling of Fathom's lab-in-the-loop capabilities and the expansion of internal discovery programs in high-impact diseases. The company's leadership has collectively advanced 19 drugs to the clinic, including seven FDA-approved medicines. Fathom has an active pipeline and multiple external discovery partnerships..

新资金将加速 Fathom 的环路实验室能力的扩展，以及在高影响力疾病领域的内部发现项目的扩展。公司领导层共同推进了 19 种药物进入临床阶段，其中包括七种 FDA 批准的药物。Fathom 拥有活跃的研发管线和多个外部发现合作伙伴关系。

'We started Fathom to build a flywheel for new small molecule medicines that previously seemed impossible,' said Dr. Xu.

“我们创立Fathom是为了打造一个以前似乎不可能实现的新型小分子药物的飞轮，”徐博士说。

Fathom's two other co-founders, Jesús Izaguirre, PhD, previously at Roivant Discovery and Silicon Therapeutics, and Yujie Wu, PhD, previously at Roivant Discovery and Schrödinger, are pioneers in building molecular models for drug discovery.

Fathom的另外两位联合创始人，曾就职于Roivant Discovery和Silicon Therapeutics的耶稣·伊萨吉雷博士以及曾就职于Roivant Discovery和Schrödinger的吴玉洁博士，是构建药物发现分子模型的先驱。

'Fathom stood out to us as a company tackling one of the most ambitious and technically difficult challenges in biotech — already showing the real ability to translate computational results into molecules with promising therapeutic profiles,' said Ethan Kurzweil, Co-Founder and Managing Partner, Chemistry.

“Fathom 让我们眼前一亮，这是一家致力于应对生物技术领域最具雄心且技术难度最高的挑战的公司——已经展现出将计算结果转化为具有前景的治疗分子的真实能力，”Chemistry 的联合创始人兼管理合伙人 Ethan Kurzweil 表示。

'We're excited to back Fathom as they work to build medicines that would be impossible to create any other way.'.

“我们很兴奋能够支持Fathom，因为他们致力于研发出其他方式无法创造的药物。”

New Appointments

新任命

Alongside the financing, Fathom announced two additions to its leadership.

除了融资，Fathom 还宣布了其领导层的两位新成员。

Mandana Honu, PhD, has joined as Chief Business Officer. Dr. Honu is a strategic advisor to Sutter Hill Ventures and previously held roles as Head of Business Development at Protillion Biosciences, Chief Scientific Officer at Kaleidoscope Bio, and Head of Scientific Assessments and Corporate Business Development at Resilience..

曼达娜·霍努博士已加入公司担任首席商务官。霍努博士是萨特希尔风险投资公司的战略顾问，曾担任普罗蒂隆生物科学公司的商务发展主管、万花筒生物公司的首席科学官以及韧性公司的科学评估和企业商务发展主管。

Diala Ezzeddine, PhD, a seasoned biotech entrepreneur and executive, has joined the board of directors. Dr. Ezzeddine brings over 20 years of experience in founding and scaling biotech companies at the cutting edge of drug discovery innovation, including X-Chem Pharmaceuticals and Magnet Biomedicine..

Diala Ezzeddine博士，一位资深的生物技术企业家和高管，已加入董事会。Ezzeddine博士在创立和发展处于药物发现创新前沿的生物技术公司方面拥有超过20年的经验，包括X-Chem Pharmaceuticals和Magnet Biomedicine。

Scientific Advisory Board

科学顾问委员会

Fathom has established a Scientific Advisory Board (SAB) to guide the company's drug design strategy and pipeline development. Members include Ian Taylor, PhD (former Chief Scientific Officer of Arvinas); Dimitris Agrafiotis, PhD, FRSC (Director at Arsenal Capital Partners, formerly Chief Information Officer Novartis Institutes for BioMedical Research and Chief Digital Officer at Generate Biomedicines); and Bruce Zetter, PhD (Professor of Cancer Biology at Harvard University and Boston Children's Hospital)..

Fathom 成立了科学顾问委员会 (SAB)，以指导公司的药物设计战略和管线开发。成员包括伊恩·泰勒博士（前Arvinas首席科学官）；迪米特里斯·阿格拉菲奥蒂斯博士，FRSC（Arsenal Capital Partners董事，曾担任诺华生物医学研究所首席信息官及Generate Biomedicines首席数字官）；以及布鲁斯·泽特博士（哈佛大学和波士顿儿童医院癌症生物学教授）。

'I welcome this extraordinary team of scientific and business leaders to our internal leadership, board, and SAB, who bring deep expertise and complementary perspectives across biology, technology, partnering, and translational medicine,' said Dr. Xu. 'Each of these leaders shares our ambitious goal of pushing the molecular frontier to deliver better therapies to patients, and their combined expertise will accelerate the process of taking each idea to regulatory approval.'.

“我欢迎这支由科学和商业领袖组成的非凡团队加入我们的内部领导层、董事会和科学顾问委员会，他们带来了在生物学、技术、合作和转化医学方面的深厚专业知识和互补视角，”徐博士说。“这些领导者每一位都与我们有着相同的宏伟目标，即推动分子前沿以向患者提供更好的治疗方案，他们的综合专业知识将加速每个想法获得监管批准的过程。”

About Fathom Therapeutics

关于Fathom Therapeutics

Fathom Therapeutics is a drug design company that uses physics-based simulations and AI to model protein motion and interactions at atomic resolution. Its Microcosmos platform simulates protein dynamics, producing the data needed to design small molecules with differentiated therapeutic effects and reduced off-target risk.

Fathom Therapeutics是一家药物设计公司，利用基于物理的模拟和人工智能以原子分辨率建模蛋白质运动和相互作用。其Microcosmos平台模拟蛋白质动力学，生成设计具有差异化治疗效果和降低脱靶风险的小分子所需的数据。

The company has an active internal pipeline, multiple discovery partnerships, and has advanced its lead program into animal efficacy studies. Fathom was founded by the team behind the Anton supercomputer and the most widely used software for predicting protein-drug binding. The company is headquartered in New York, with a second office in Boston..

该公司拥有活跃的内部研发管道、多个发现合作伙伴关系，并已将其主导项目推进到动物效力研究阶段。Fathom 由 Anton 超级计算机背后团队以及用于预测蛋白质-药物结合的最广泛使用软件的创始团队创立。公司总部位于纽约，在波士顿设有第二个办公室。

Media contact:

媒体联系人：

Ryan Flinn

瑞安·弗林

In Like Flinn Communications

如同弗林通信

[email protected]

电子邮件地址

SOURCE Atommap Corporation

来源：Atommap Corporation

21

21

%

%

more press release views with

更多新闻发布观点

Request a Demo

请求演示